Indian manufacture of new generic antiretrovirals: Implications for global access to anti-HIV drugs

HIV Therapy

Volumn 4, Issue 1, 2010, Pages 1-4

  Venkatesh, Kartik K ^a   Kumarasamy, Nagalingeswaran ^b   Mayer, Kenneth H ^a  

^a BROWN UNIVERSITY   (United States)

^b YRG CENTRE FOR AIDS RESEARCH AND EDUCATION   (India)

Author keywords

[No Author keywords available]

Indexed keywords

DARUNAVIR; ETRAVIRINE; GENERIC DRUG; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; MARAVIROC; TENOFOVIR;

ANTIVIRAL ACTIVITY; CD4+ T LYMPHOCYTE; COST EFFECTIVENESS ANALYSIS; DRUG FORMULARY; DRUG MANUFACTURE; EDITORIAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDIAN;

EID: 74749104562     PISSN: 17584310     EISSN: None     Source Type: Journal    
DOI: 10.2217/hiv.09.55     Document Type: Editorial

References (19)

1. Majumdar B: India patent rejections welcomed by HIV/AIDS groups. Reuters, 9 September (2009).
2. Butler D: India says no to HIV drug patents: patent office rejects applications from two US drug companies. Nat. News, 3 September (2009).
3. Dionisio D, Fabbri C, Messeri D: HIV drug policies and south markets: settling controversies. Therapy 5(5), 707-717 (2008).
4. Havlir D, Hammer SM: Patents versus patients? Antiretroviral therapy in India. N. Engl. J. Med. 353(8), 749-751 (2005).
5. Quinn T: HIV epidemiology and the effects of antiviral therapy on long-term consequences. AIDS 22(Suppl. 3), S7-S12 (2008).
6. Nunn A, Fonseca EM, Bastos FI, Gruskin S, Salomon JA: Evolution of antiretroviral drug costs in brazil in the context of free and universal access to aids treatment. PLoS Med. 4(11), e305 (2007).
7. Kitahata M, Gange SJ, Abraham AG et al.; NA-ACCORD Investigators: Effect of early versus deferred antiretroviral therapy for HIV on survival. N. Engl. J. Med. 360(18), 1815-1826 (2009).
8. Harries A, Schouten EJ, Libamba E: Scaling up antiretroviral treatment in resource-poor settings. Lancet 367(9525), 1870-1872 (2006).
9. Kumarasamy N, Solomon S, Chaguturu SK et al.: The safety, tolerability, and effectiveness of generic antiretroviral drug regimens for HIV-infected patients in south India. AIDS 17, 2265-2271 (2003).
10. Laurent C, Kouanfack C, Koulla-Shiro S et al.: Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial. Lancet 264, 29-34 (2004).
11. Bartlett J, Muro EP: Generic and branded drugs for the treatment of people living with HIV/AIDS. J. Int. Assoc. Physicians AIDS Care 6(1), 15-23 (2007).
12. Hirsch M: Initiating therapy: when to start, what to use. J. Infect. Dis. 197(Suppl. 3), S252-S260 (2008).
13. Orrell C, Harling G, Lawn SD et al.: Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited. Antivir. Ther. 12(1), 83-88 (2007).
14. Renaud-Théry F, Nguimfack BD, Vitoria M et al.: Use of antiretroviral therapy in resource-limited countries in 2006: distribution and uptake of first- and second-line regimens. AIDS 21(Suppl. 4), S89-S95 (2007).
15. Beck E, Vitoria M, Mandalia S, Crowley S, Gilks CF, Souteyrand Y: National adult antiretroviral therapy guidelines in resource-limited countries: concordance with 2003 WHO guidelines? AIDS 20(11), 1497-1502 (2006).
16. Waning B, Kaplan W, King AC, Leufkens HG, Fox MP: Global strategies to reduce the price of antiretroviral medicines: evidence from transactional databases. Bull. World Health Organ. 87(7), 520-528 (2009).
17. Vasan A, Hoos D, Mukherjee JS, Farmer PE, Rosenfield AG, Perriëns JH: The pricing and procurement of antiretroviral drugs: an observational study of data from the Global Fund. Bull. World Health Organ. 84(5), 393-398 (2006).
18. MSF response to India's rejection of patents on key HIV/AIDS drugs (2009). http://www.msfaccess.org/main/accesspatents/msf-response-to-india-s- rejection-ofpatents-on-key-hivaids-drugs/
19. United Nations. 2008 update on the global AIDS epidemic. www.unaids.org/en/KnowledgeCentre/HIVData/GlobalReport/2008/2008-Global-report. asp